经典文献 l 2022 2型糖尿病:挑战和未来方向 精准医学和未来治疗选择 Lancet 2022; 400: 1803–20 编译:陈康 Mahajan A, Taliun D, Thurner M, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet 2018; 50: 1505–13. Cai L, Wheeler E, Kerrison ND, et al. Genome-wide association analysis of type 2 diabetes in the EPIC-InterAct study. Sci Data 2020; 7: 393. Strausz S, Ruotsalainen S, Ollila HM, et al. Genetic analysis of obstructive sleep apnoea discovers a strong association with cardiometabolic health. Eur Respir J 2021; 57:2003091 Lotta LA, Wittemans LBL, Zuber V, et al. Association of genetic variants related to gluteofemoral vs abdominal fat distribution with type 2 diabetes, coronary disease, and cardiovascular risk factors. JAMA 2018; 320:2553–63 Xie F, Chan JC, Ma RC. Precision medicine in diabetes prevention, classification and management. J Diabetes Investig 2018; 9:998–1015 Chung WK, Erion K, Florez JC, et al. Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020;63: 1671–93/公众号内译文:指南共识|2020糖尿病精准医学:ADA/EASD共识报告** 临床进展 l 2022糖尿病精准医学的国际视野和未来愿景 l ADA/EASD糖尿病精准医学倡议** 2型糖尿病精准诊断 Mohanty S, Rashid MHA, Mohanty C, Swayamsiddha S. Modern computational intelligence based drug repurposing for diabetes epidemic. Diabetes Metab Syndr 2021; 15: 102180 利用肠促胰岛素轴的药物 Bossart M, Wagner M, Elvert R, et al. Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. Cell Metab 2022;34: 59–74 Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet2021; 398: 2160–72 基于这些发现,在肥胖管理和糖尿病控制的领域,已经在进行各种组合的临床试验,例如: 内分泌医学史 l 胰岛素100年:胰岛素治疗的过去、现在和未来(最终专业版)** 胰岛素的过去、现在和未来挑战 (绿色部分是未来方向) Heise T. The future of insulin therapy. Diabetes Res Clin Pract 2021; 175: 108820 Rosenstock J, Bajaj HS, Janež A, et al. Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med 2020; 383: 2107–16 Rosenstock J, Del Prato S. Basal weekly insulins: the way of the future! Metabolism 2022; 126:154924. Frias JP, Chien J, Zhang Q, et al. Once weekly basal insulin Fc (BIF) is safe and efficacious in patients with type 2 diabetes mellitus (T2DM) previously treated with basal insulin. J Endocr Soc 2021; 5 (suppl 1): A448–49 |
|